Results 21 to 30 of about 519,893 (158)

Safety of COVID-19 mRNA-1273 booster doses in Asian populations: A literature review of post-marketing observational studies [PDF]

Human Vaccines & Immunotherapeutics
Real-world data on the safety of COVID-19 booster doses in Asian populations are needed to inform national immunization programs. The safety profile of mRNA-1273 (Moderna, Inc.) was evaluated using post-marketing observational data.
Chris Clarke, Daina Esposito, Veronica Urdaneta, Piyali Mukherjee, Amanda K. Buttery   +4 more
doaj   +2 more sources

Comparative immunogenicity of mRNA-1273 and BNT162b2 SARS-CoV-2 bivalent booster vaccines in US nursing home residents [PDF]

Human Vaccines & Immunotherapeutics
Nursing home residents (NHRs) remain among the most vulnerable to severe outcomes from SARS-CoV-2 infection. While mRNA-1273 (Spikevax, Moderna) and BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccines are widely used in this population, comparative data on ...
Olajide J. Olagunju, Oladayo A. Oyebanji, Debbie Keresztesy, Dennis Wilk, Evan Dickerson, Tiffany Wallace, Laurel Holland, Mike Payne, Ellen See, Chia Jung Li, Eunice Lim, Yasin Abul, Clare Nugent, Alejandro B. Balazs, Jürgen Bosch, Christopher L. King, Brigid Wilson, Stefan Gravenstein, David H. Canaday   +18 more
doaj   +2 more sources

Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera [PDF]

Front Immunol
IntroductionThe first vaccines approved against SARS-CoV-2, mRNA-1273 and BNT162b2, utilized mRNA platforms. However, little is known about the proteomic markers and pathways associated with host immune responses to mRNA vaccination.
Nancy V. Roche, Uma Mudunuri, Ligia A. Pinto, Thomas E. Hickey, Brian A. Sellers, Heidi A. Hempel, Keyur Talsania, Troy J. Kemp, James M. Cherry   +8 more
core   +2 more sources

mRNA-1273 COVID-19 vaccine induces CD4+ T-cell responses among solid organ transplant recipients [PDF]

Front Immunol
BackgroundCell-mediated immunity may provide durable protection against severe COVID-19, including among solid organ transplant recipients (SOTRs). This exploratory analysis in the open-label phase 3b trial evaluated cell-mediated immunity of mRNA-1273 ...
Dina Stolman, M. Juliana McElrath, Bethany Girard, Elizabeth de Windt, Jamil R. Azzi, Jacqueline M. Miller, Rituparna Das, Frances Priddy, Amparo L. Figueroa, Stephen C. De Rosa, Uma Siangphoe   +10 more
core   +2 more sources

Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE [PDF]

Infectious Diseases and Therapy
Introduction Immunocompromised (IC) patients mount poor immune responses to vaccination. Higher-dose coronavirus disease 2019 (COVID-19) vaccines may offer increased immunogenicity.
Sushma Kavikondala, Katrin Haeussler, Xuan Wang, Anne Spellman, Mary T. Bausch-Jurken, Pawana Sharma, Mohammadreza Amiri, Anna Krivelyova, Sonam Vats, Maria Nassim, Nitendra Kumar, Nicolas Van de Velde   +11 more
doaj   +2 more sources

Clinical Course, Outcomes, and Risk Factors of Myocarditis and Pericarditis Following Administration of mRNA-1273 Vaccination: A Protocol for a Federated Real-World Evidence Vaccine Safety Study Using Data from Five European Data Sources [PDF]

Vaccines
Background: Myocarditis and pericarditis are recognised risks following COVID-19 vaccination, including the mRNA-1273 vaccine. Most cases occur shortly following the second dose of this vaccine, and incidence is highest among young males. However, little
Laura C. Zwiers, Diederick E. Grobbee, Rob Schneijdenberg, Corine Baljé, Samantha St. Laurent, Daina B. Esposito, Lei Zhu, Veronica V. Urdaneta, Magalie Emilebacker, Daniel Weibel, Felipe Villalobos, Carlo Alberto Bissacco, Arantxa Urchueguía Fornes, Juan José Carreras-Martínez, Anteneh A. Desalegn, Angela Lupattelli, Lei Wang, Jannik Wheler, Vera Ehrenstein, Denise Morris, Catherine Fry, Marjolein Jansen, Brianna M. Goodale, David S. Y. Ong   +23 more
doaj   +2 more sources

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients [PDF]

, 2022
Objective: Anti-CD20-treated patients are at risk of a reduced humoral immune response during the SARS-CoV-2 pandemic. Our aim was to compare the antibody response after two vaccinations with the mRNA vaccines BNT162b2 or mRNA-1273 in patients with ...
Kamber, Nicole, Helly Hammer, Hammer, Helly, Diem, Lara, Kamm, Christian P, Salmen, Anke, Hoepner, Robert, Robert Hoepner, Nicole Kamber, Stephen L. Leib, Friedli, Christoph, Andrew Chan, Kamm, Christian P., Christoph Friedli, Christian P. Kamm, Anke Salmen, Chan, Andrew, Leib, Stephen L., Lara Diem, Suter-Riniker, Franziska, Leib, Stephen L, Franziska Suter-Riniker   +21 more
core   +2 more sources

Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase [PDF]

, 2021
BACKGROUND At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19).
Neuzil, KM, Ledgerwood, JE, Babiker, A, Gorman, R, Janes, H, Mytle, N, Rankin, B, Schödel, F, Levine, MM, Clark, J, Pavetto, C, Ellenberg, SS, Kennelly, C, Pajon, R, Tsiatis, AA, Whitley, RJ, Manzo, D, Faugno, A, Zhou, H, Horwith, G, Feldman, G, Doblecki-Lewis, S, Zervos, M, Griffin, M, Kalil, J, Mascola, JR, Baden, LR, Han, S, Huynh, C, Graham, BS, Campbell, TB, Levin, M, Treanor, J, Cooper, LA, Makgoba, MW, Deng, W, El Sahly, HM, Tomassini, JE, Essink, B, Moore, RH, Clouting, H, Lipsitz, L, Martin, JM, Follmann, D, Leav, B, Anderson, EJ, Fix, A, Eder, F, Rosenberg, ES, August, A, Hamill, RJ, Marovich, M, Jackson, LA, Tong, X, Bruno, R, Gilbert, P, Miller, J, Corey, L, Han-Conrad, L, Joffe, S, Fichtenbaum, CJ, Polakowski, L, Hamilton, H   +62 more
core   +5 more sources

Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273

Microbiology Spectrum, 2022
While mRNA vaccines are highly efficacious against short-term COVID-19, long-term immunogenicity is less clear. We compared humoral immunogenicity between BNT162b2 and mRNA-1273 vaccines 6 months after the first vaccine dose, examining the wild-type ...
Brian Grunau, Liam Golding, Martin A. Prusinkiewicz, Michael Asamoah-Boaheng, Richard Armour, Ana Citlali Marquez, Agatha N. Jassem, Vilte Barakauskas, Sheila F. O’Brien, Steven J. Drews, Scott Haig, Pascal M. Lavoie, David M. Goldfarb   +12 more
doaj   +1 more source

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

, 2021
BACKGROUND: Vaccines are urgently needed to prevent the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and immunogenicity of vaccine candidate mRNA-1273, encoding the prefusion-stabilized spike ...
McPhee, Roderick, Bennett, Hamilton, Pajon, Rolando, Chu, Laurence, Nestorova, Biliana, mRNA-1273 Study Group, Huang, Wenmei, Leav, Brett   +7 more
core   +1 more source